Phase II Trial of Gleevec (Imatinib Mesylate, STI571) Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive, Extensive-Stage Small Cell Lung Cancer.

Trial Profile

Phase II Trial of Gleevec (Imatinib Mesylate, STI571) Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive, Extensive-Stage Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2010

At a glance

  • Drugs Imatinib (Primary) ; Cisplatin; Irinotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2010 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
    • 15 Nov 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 19 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top